| VIRX Stock | | | USD 0.15 0.01 7.14% |
Viracta Therapeutics financial indicator trend analysis is much more than just breaking down Viracta Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Viracta Therapeutics is a good investment. Please check the relationship between Viracta Therapeutics Total Current Assets and its Accounts Payable accounts. Check out
World Market Map to better understand how to build diversified portfolios, which includes a position in Viracta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in metropolitan statistical area.
For more information on how to buy Viracta Stock please use our
How to Invest in Viracta Therapeutics guide.
Total Current Assets vs Accounts Payable
Total Current Assets vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of
Viracta Therapeutics Total Current Assets account and
Accounts Payable. At this time, the significance of the direction appears to have weak relationship.
The correlation between Viracta Therapeutics' Total Current Assets and Accounts Payable is 0.32. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Viracta Therapeutics, assuming nothing else is changed. The correlation between historical values of Viracta Therapeutics' Total Current Assets and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Viracta Therapeutics are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Total Current Assets i.e., Viracta Therapeutics' Total Current Assets and Accounts Payable go up and down completely randomly.
Correlation Coefficient | 0.32 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.
Accounts Payable
An accounting item on the balance sheet that represents Viracta Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Viracta Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from Viracta Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Viracta Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out
World Market Map to better understand how to build diversified portfolios, which includes a position in Viracta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in metropolitan statistical area.
For more information on how to buy Viracta Stock please use our
How to Invest in Viracta Therapeutics guide.
Sales General And Administrative To Revenue is likely to rise to 53.81 in 2024, whereas
Selling General Administrative is likely to drop slightly above 13.7
M in 2024.
Viracta Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Viracta Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Viracta Therapeutics fundamental ratios Accounts
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Viracta Stock Analysis
When running Viracta Therapeutics' price analysis, check to
measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to
predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.